where 0  is the mean EIR for adults, b is the probability of infection upon being bitten by an 29 infectious mosquito and  and 0 a parameterise the change in the rate of being bitten as a function 30 of age. 31
The effects of immunity are included in the transmission model at a number of stages. These are: 32 i)
Maternal immunity -A degree of protection against infection after being born is 33 conferred from mother to child. This protection decreases the probability of infection 34 upon being bitten by an infectious mosquito ( b ). The level of protection is a function of 35 the mother's immunity and wanes at a given rate. 36 3 ii)
Blood stage immunity -Reduces the probability of developing clinical disease upon 37 infection ( ). Reduces blood stage parasite densities, leading to decreased detectability 38 and decreased onwards infection of mosquitoes. 39
iii)
Pre-erythrocytic immunity -Reduces the probability of infection upon being bitten by an 40 infectious mosquito ( b ) in older children and adults. 41
Full details of the functional implementation of immunity in the transmission model are found in 42 Griffin et al (2014) . [2] Human parameters are shown in Table 1 . 43 5   1   3   13  11  1  1   3  1  3  3  1  3  13 
.
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where ω is a normalising constant for the biting rate over all ages, Q0 denotes the level of 65 anthropophagy and δ the mean time between feeds. Human-to-vector infectivity is lagged l t behind 66 human infection, to account for the period of time between a human becoming infected and the 67 appearance of gametocytes (the infectious stage to mosquitoes) in the bloodstream. 68
The progression of infection within mosquitoes can then be described with the following set of 69 differential equations: 70 And the EIR is defined as: 78
Mosquito parameters are shown in Table 2 . 80 Table 3 82
Vector profiles
83
We represent the range of different vector species compositions observed across sub-Saharan Africa 84 using four vector profiles. The profiles are characterised by four parameters the proportion of 85 human-biting ( 0 Q ), indoor biting ( I  ), indoor resting (  ), and biting on humans in bed ( B  ). The 86 probabilities for each profile are defined in Table 3 . 87 8 With the probabilities defined above, excluding natural vector mortality, a matrix of potential 114 outcome probabilities can be produced (Table 4) . 115 Table 4 . Vector control outcome probability matrix.
116
Definition IRS only LLINs only IRS plus LLINs Probability of successful feeding 1
(1 )
Seasonal malaria chemoprevention 
RTS,S

127
We assumed children would be vaccinated with 4 doses at 6, 7.5, 9 and 27 months. Figure S5 . 163
Health production functions
164
We describe the procedure for estimating the empirically-derived production functions (for IRS, 165
Vaccine and SMC) below. We assumed that the response (coverage of a given intervention), was 166 beta distributed with mean 
Where, C is the coverage achieved for a given spend per person reached, P. The commodity cost and 172 baseline variable cost is denoted by U and N respectively and Cτ represents the threshold coverage 173 above which delivery costs increase. We restricted C  the lower coverage bound for each 174 intervention to avoid issues of economies of scale at low coverage levels. The function in equation 175
(1.17) represents the inverse of the functions in equations (1.1-1.2) in the main text. 176
For this parameterisation of the beta distribution we have 177
The log-likelihood, for n independent samples is 179 were adjusted for within-country (non-GAVI) DTP3 spend as reported in the country specific WHO-203 UNICEF comprehensive multi-year plan (cMYP).
[11] The spending estimates were then standardised 204 with respect to the estimated population of children under one years old [12] providing an estimate 205 of the absolute spend on DTP vaccination per child under one years old. To generalise the 206 production function for any vaccine, the spend was then divided by the mean cost of a full DTP 207 vaccination course, as reported in the cMYPs, with the result being a cost-multiplier that could be 208 applied to the cost of a specified full vaccination course. 209
For each country, estimates of spend and coverage across multiple years may not be independent. 210 Therefore mean estimates of coverage and spend for each country were calculated and used to fit 211 the model. Confidence intervals surrounding these estimates were 95% exact binomial (for 212 coverage) and log-normal (for spend). Table  228 7. 229 Table 7 . Prior and posterior distributions for estimated health production functions. 
